Eintrag weiter verarbeiten
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.
Gespeichert in:
Zeitschriftentitel: | Journal of Clinical Oncology |
---|---|
Personen und Körperschaften: | , , , , , , , , , , , |
In: | Journal of Clinical Oncology, 31, 2013, 15_suppl, S. 602-602 |
Format: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
Schlagwörter: |
author_facet |
Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus |
---|---|
author |
Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus |
spellingShingle |
Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus Journal of Clinical Oncology Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. Cancer Research Oncology |
author_sort |
hanker, lars christian |
spelling |
Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2013.31.15_suppl.602 <jats:p> 602 </jats:p><jats:p> Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-therapy in this ongoing study. Progression-free survival (PFS) was assessed by the investigator. Results: The median disease-free interval (calculated from the time of resection of the primary tumor to diagnosis of local recurrence/MBC) was 3.1 years. Median duration of re-therapy with T was 9.3 months. The median PFS of all patients was 10.1 months (95% confidence interval (CI), 8.5 to 13.1). PFS for pts with only locally recurrent disease (n= 33) was 23.6 months. PFS for MBC pts (n=141) was 8.9 months (95% CI, 7.4 to 10.6). For pts with visceral metastases (n=96) a PFS of 8.0 months compared to 10.1 months in patients with only non-visceral (n=45) was recorded. 104 pts were re-treated with T + CT (>70% paclitaxel, vinorelbine, capecitabine or docetaxel alone; PFS= 9.3 months), 26 pts with T + hormonal therapy (HT) (mostly anastrozole, fulvestrant, exemestane, letrozole or tamoxifen; PFS=10.1 months), 24 pts with T+CT+HT (PFS= 19.9 months) and 20 pts with T monotherapy (PFS= 9.4 months). Conclusions: This study provides clinical evidence that re-application of T in combination with either CT, HT or alone is effective in the routine treatment of patients with MBC and/or locally recurrent disease. The benefit observed for pts receiving first-line treatment with T in combination with taxane in pivotal trials as well as recently published data seems comparable to the presented results of pts receiving T re-therapy. </jats:p> Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. Journal of Clinical Oncology |
doi_str_mv |
10.1200/jco.2013.31.15_suppl.602 |
facet_avail |
Online Free |
finc_class_facet |
Medizin |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC42MDI |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC42MDI |
institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
imprint |
American Society of Clinical Oncology (ASCO), 2013 |
imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2013 |
issn |
0732-183X 1527-7755 |
issn_str_mv |
0732-183X 1527-7755 |
language |
English |
mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
match_str |
hanker2013efficacyoftrastuzumabretherapyinroutinetreatmentofher2positivebreastcancerpatientswhorelapsedaftercompletedneoadjuvantantiher2therapy |
publishDateSort |
2013 |
publisher |
American Society of Clinical Oncology (ASCO) |
recordtype |
ai |
record_format |
ai |
series |
Journal of Clinical Oncology |
source_id |
49 |
title |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_unstemmed |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_full |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_fullStr |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_full_unstemmed |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_short |
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_sort |
efficacy of trastuzumab re-therapy in routine treatment of her2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-her2 therapy. |
topic |
Cancer Research Oncology |
url |
http://dx.doi.org/10.1200/jco.2013.31.15_suppl.602 |
publishDate |
2013 |
physical |
602-602 |
description |
<jats:p> 602 </jats:p><jats:p> Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-therapy in this ongoing study. Progression-free survival (PFS) was assessed by the investigator. Results: The median disease-free interval (calculated from the time of resection of the primary tumor to diagnosis of local recurrence/MBC) was 3.1 years. Median duration of re-therapy with T was 9.3 months. The median PFS of all patients was 10.1 months (95% confidence interval (CI), 8.5 to 13.1). PFS for pts with only locally recurrent disease (n= 33) was 23.6 months. PFS for MBC pts (n=141) was 8.9 months (95% CI, 7.4 to 10.6). For pts with visceral metastases (n=96) a PFS of 8.0 months compared to 10.1 months in patients with only non-visceral (n=45) was recorded. 104 pts were re-treated with T + CT (>70% paclitaxel, vinorelbine, capecitabine or docetaxel alone; PFS= 9.3 months), 26 pts with T + hormonal therapy (HT) (mostly anastrozole, fulvestrant, exemestane, letrozole or tamoxifen; PFS=10.1 months), 24 pts with T+CT+HT (PFS= 19.9 months) and 20 pts with T monotherapy (PFS= 9.4 months). Conclusions: This study provides clinical evidence that re-application of T in combination with either CT, HT or alone is effective in the routine treatment of patients with MBC and/or locally recurrent disease. The benefit observed for pts receiving first-line treatment with T in combination with taxane in pivotal trials as well as recently published data seems comparable to the presented results of pts receiving T re-therapy. </jats:p> |
container_issue |
15_suppl |
container_start_page |
602 |
container_title |
Journal of Clinical Oncology |
container_volume |
31 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792322789301026826 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T11:23:29.051Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Efficacy+of+trastuzumab+re-therapy+in+routine+treatment+of+HER2-positive+breast+cancer+patients+who+relapsed+after+completed+%28neo-%29adjuvant+anti-HER2+therapy.&rft.date=2013-05-20&genre=article&issn=1527-7755&volume=31&issue=15_suppl&spage=602&epage=602&pages=602-602&jtitle=Journal+of+Clinical+Oncology&atitle=Efficacy+of+trastuzumab+re-therapy+in+routine+treatment+of+HER2-positive+breast+cancer+patients+who+relapsed+after+completed+%28neo-%29adjuvant+anti-HER2+therapy.&aulast=Schmidt&aufirst=Marcus&rft_id=info%3Adoi%2F10.1200%2Fjco.2013.31.15_suppl.602&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792322789301026826 |
author | Hanker, Lars Christian, Hitschold, Thomas, Hesse, Tobias, Grafe, Andrea, Foerster, Frank Gerhard, Schroeder, Jan Klaus, Janssen, Jan, Reichert, Dietmar Arno, Hielscher, Carsten, Greinemann, Jasmin, Borquez, David Julian, Schmidt, Marcus |
author_facet | Hanker, Lars Christian, Hitschold, Thomas, Hesse, Tobias, Grafe, Andrea, Foerster, Frank Gerhard, Schroeder, Jan Klaus, Janssen, Jan, Reichert, Dietmar Arno, Hielscher, Carsten, Greinemann, Jasmin, Borquez, David Julian, Schmidt, Marcus, Hanker, Lars Christian, Hitschold, Thomas, Hesse, Tobias, Grafe, Andrea, Foerster, Frank Gerhard, Schroeder, Jan Klaus, Janssen, Jan, Reichert, Dietmar Arno, Hielscher, Carsten, Greinemann, Jasmin, Borquez, David Julian, Schmidt, Marcus |
author_sort | hanker, lars christian |
container_issue | 15_suppl |
container_start_page | 602 |
container_title | Journal of Clinical Oncology |
container_volume | 31 |
description | <jats:p> 602 </jats:p><jats:p> Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-therapy in this ongoing study. Progression-free survival (PFS) was assessed by the investigator. Results: The median disease-free interval (calculated from the time of resection of the primary tumor to diagnosis of local recurrence/MBC) was 3.1 years. Median duration of re-therapy with T was 9.3 months. The median PFS of all patients was 10.1 months (95% confidence interval (CI), 8.5 to 13.1). PFS for pts with only locally recurrent disease (n= 33) was 23.6 months. PFS for MBC pts (n=141) was 8.9 months (95% CI, 7.4 to 10.6). For pts with visceral metastases (n=96) a PFS of 8.0 months compared to 10.1 months in patients with only non-visceral (n=45) was recorded. 104 pts were re-treated with T + CT (>70% paclitaxel, vinorelbine, capecitabine or docetaxel alone; PFS= 9.3 months), 26 pts with T + hormonal therapy (HT) (mostly anastrozole, fulvestrant, exemestane, letrozole or tamoxifen; PFS=10.1 months), 24 pts with T+CT+HT (PFS= 19.9 months) and 20 pts with T monotherapy (PFS= 9.4 months). Conclusions: This study provides clinical evidence that re-application of T in combination with either CT, HT or alone is effective in the routine treatment of patients with MBC and/or locally recurrent disease. The benefit observed for pts receiving first-line treatment with T in combination with taxane in pivotal trials as well as recently published data seems comparable to the presented results of pts receiving T re-therapy. </jats:p> |
doi_str_mv | 10.1200/jco.2013.31.15_suppl.602 |
facet_avail | Online, Free |
finc_class_facet | Medizin |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC42MDI |
imprint | American Society of Clinical Oncology (ASCO), 2013 |
imprint_str_mv | American Society of Clinical Oncology (ASCO), 2013 |
institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
issn | 0732-183X, 1527-7755 |
issn_str_mv | 0732-183X, 1527-7755 |
language | English |
last_indexed | 2024-03-01T11:23:29.051Z |
match_str | hanker2013efficacyoftrastuzumabretherapyinroutinetreatmentofher2positivebreastcancerpatientswhorelapsedaftercompletedneoadjuvantantiher2therapy |
mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
physical | 602-602 |
publishDate | 2013 |
publishDateSort | 2013 |
publisher | American Society of Clinical Oncology (ASCO) |
record_format | ai |
recordtype | ai |
series | Journal of Clinical Oncology |
source_id | 49 |
spelling | Hanker, Lars Christian Hitschold, Thomas Hesse, Tobias Grafe, Andrea Foerster, Frank Gerhard Schroeder, Jan Klaus Janssen, Jan Reichert, Dietmar Arno Hielscher, Carsten Greinemann, Jasmin Borquez, David Julian Schmidt, Marcus 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2013.31.15_suppl.602 <jats:p> 602 </jats:p><jats:p> Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-therapy in this ongoing study. Progression-free survival (PFS) was assessed by the investigator. Results: The median disease-free interval (calculated from the time of resection of the primary tumor to diagnosis of local recurrence/MBC) was 3.1 years. Median duration of re-therapy with T was 9.3 months. The median PFS of all patients was 10.1 months (95% confidence interval (CI), 8.5 to 13.1). PFS for pts with only locally recurrent disease (n= 33) was 23.6 months. PFS for MBC pts (n=141) was 8.9 months (95% CI, 7.4 to 10.6). For pts with visceral metastases (n=96) a PFS of 8.0 months compared to 10.1 months in patients with only non-visceral (n=45) was recorded. 104 pts were re-treated with T + CT (>70% paclitaxel, vinorelbine, capecitabine or docetaxel alone; PFS= 9.3 months), 26 pts with T + hormonal therapy (HT) (mostly anastrozole, fulvestrant, exemestane, letrozole or tamoxifen; PFS=10.1 months), 24 pts with T+CT+HT (PFS= 19.9 months) and 20 pts with T monotherapy (PFS= 9.4 months). Conclusions: This study provides clinical evidence that re-application of T in combination with either CT, HT or alone is effective in the routine treatment of patients with MBC and/or locally recurrent disease. The benefit observed for pts receiving first-line treatment with T in combination with taxane in pivotal trials as well as recently published data seems comparable to the presented results of pts receiving T re-therapy. </jats:p> Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. Journal of Clinical Oncology |
spellingShingle | Hanker, Lars Christian, Hitschold, Thomas, Hesse, Tobias, Grafe, Andrea, Foerster, Frank Gerhard, Schroeder, Jan Klaus, Janssen, Jan, Reichert, Dietmar Arno, Hielscher, Carsten, Greinemann, Jasmin, Borquez, David Julian, Schmidt, Marcus, Journal of Clinical Oncology, Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy., Cancer Research, Oncology |
title | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_full | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_fullStr | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_full_unstemmed | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_short | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
title_sort | efficacy of trastuzumab re-therapy in routine treatment of her2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-her2 therapy. |
title_unstemmed | Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. |
topic | Cancer Research, Oncology |
url | http://dx.doi.org/10.1200/jco.2013.31.15_suppl.602 |